ITMI971091A1 - PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES - Google Patents
PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES Download PDFInfo
- Publication number
- ITMI971091A1 ITMI971091A1 IT97MI001091A ITMI971091A ITMI971091A1 IT MI971091 A1 ITMI971091 A1 IT MI971091A1 IT 97MI001091 A IT97MI001091 A IT 97MI001091A IT MI971091 A ITMI971091 A IT MI971091A IT MI971091 A1 ITMI971091 A1 IT MI971091A1
- Authority
- IT
- Italy
- Prior art keywords
- colostrum
- treatment
- oral cavity
- pharmaceutical formulations
- diseases
- Prior art date
Links
- 210000003022 colostrum Anatomy 0.000 title claims description 23
- 235000021277 colostrum Nutrition 0.000 title claims description 23
- 210000000214 mouth Anatomy 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 title claims description 10
- 201000010099 disease Diseases 0.000 title claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 241000283073 Equus caballus Species 0.000 claims description 6
- 239000002324 mouth wash Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 229960000333 benzydamine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910002055 micronized silica Inorganic materials 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Birds (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Descrizione dell'invenzione -industriale avente per titolo: "FORMULAZIONI FARMACEUTICHE CONTENENTI COLOSTRO E USO DEL COLOSTRO PER IL TRATTAMENTO DI AFFEZIONI DEL CAVO ORALE" Description of the industrial invention entitled: "PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF DISEASES OF THE ORAL CAVITY"
La presente invenzione ha per oggetto formulazioni farmaceutiche a base di colostro animale per il trattamento di affezioni del cavo orale, e l'uso del colostro per il trattamento di tali affezioni. The present invention relates to pharmaceutical formulations based on animal colostrum for the treatment of affections of the oral cavity, and the use of colostrum for the treatment of such affections.
Per "affezioni del cavo orale" si intendono, in particolare, stomatiti, stomatiti da protesi, gengiviti, periodontopatie, piorrea alveolare; mucositi, piaghe e ulcere da chemioterapia e radioterapia; infiammazioni e ulcerazioni della mucosa orale. By "affections of the oral cavity" we mean, in particular, stomatitis, prosthesis stomatitis, gingivitis, periodontal disease, alveolar pyorrhea; mucositis, sores and ulcers from chemotherapy and radiotherapy; inflammation and ulceration of the oral mucosa.
Tra i responsabili noti delle affezioni orali di cui sopra si possono citare scarsa igiene orale, infezioni, traumi meccanici locali, deficit immunitari, malattie autoimrauni, avitaminosi, agenti infettivi, tossici o irritanti, malattie sistemiche, sensibilizzazioni allergiche. Among the known responsible of the oral affections mentioned above, we can mention poor oral hygiene, infections, local mechanical trauma, immune deficiencies, autoimmune diseases, avitaminosis, infectious, toxic or irritating agents, systemic diseases, allergic sensitizations.
La terapia dipende principalmente dalla causa dell'affezione: il trattamento consiste per lo più, oltre a una maggiore cura dell'igiene orale, nella somministrazione di disinfettanti, astringenti, agenti antibatterici, come la clorexidina e sali d'ammonio quaternario; antibiotici, come penicilline e tetracicline; antimicotici, come il ketoconazolo; steroidi, opali desametazone, prednisolone e triamcinolone acetonide; anestetici locali, quali benzocaina e lidocaina; oltre all'eliminazione di eventuali fattori meccanici quali malocclusione, sostituzione di protesi ecc. The therapy mainly depends on the cause of the disease: the treatment mainly consists, in addition to a greater care of oral hygiene, in the administration of disinfectants, astringents, antibacterial agents, such as chlorhexidine and quaternary ammonium salts; antibiotics, such as penicillins and tetracyclines; antifungals, such as ketoconazole; steroids, dexamethasone opals, prednisolone and triamcinolone acetonide; local anesthetics, such as benzocaine and lidocaine; in addition to the elimination of any mechanical factors such as malocclusion, replacement of prostheses, etc.
Appare chiaro che l'uso di farmaci opali antibiotici, antimicotici e steroidi può comportare effetti collaterali indesiderati,o può essere limitato o precluso dalle condizioni del paziente.Pertanto ò fortemente sentita l'esigenza di un agente che,pur esercitando una notevole azione antiinfiammatoria e antibatterica sulle affezioni sopra citate, non provochi effetti collaterali indesiderati. It is clear that the use of antibiotic, antifungal and steroid opal drugs can lead to unwanted side effects, or can be limited or precluded by the patient's condition.Therefore, the need is strongly felt for an agent which, while exerting a significant anti-inflammatory and antibacterial on the aforementioned diseases, does not cause unwanted side effects.
La presente invenzione ha lo scopo di superare i problemi sopra indicati, mediante l'uso di formulazioni farmaceutiche topiche contenenti colostro equino o bovino o comunque di mammifero, ma preferibilmente equino, per il trattamento di affezioni del cavo orale. The present invention has the purpose of overcoming the problems indicated above, through the use of topical pharmaceutical formulations containing equine or bovine or in any case mammalian colostrum, but preferably equine, for the treatment of diseases of the oral cavity.
La presente invenzione, inoltre, ha per oggetto l'uso di colostro equino o bovino o comunque di mammifero, ma preferibilmente equino,come agente per il trattamento di affezioni del cavo orale. Furthermore, the present invention relates to the use of equine or bovine or in any case mammalian colostrum, but preferably equine, as an agent for the treatment of diseases of the oral cavity.
E' stato sorprendentemente trovato che il colostro, soministrato a pazienti con affezioni del cavo orale, agisce favorevolmente esercitando un effetto antiinfiammatorìo e ripristinando in breve tempo le condizioni fisiologiche normalmente presenti nella mucosa buccale. It has been surprisingly found that colostrum, administered to patients with affections of the oral cavity, acts favorably by exerting an anti-inflammatory effect and restoring in a short time the physiological conditions normally present in the buccal mucosa.
Le formulazioni farmaceutiche dell'invenzione comprendono formulazioni topiche contenenti colostro in polvere o liquido in quantità fino al 30% in volume della formulazione. Il colostro in polvere potrà essere in forma liofilizzata o sprayzzata. The pharmaceutical formulations of the invention comprise topical formulations containing colostrum in powder or liquid form in quantities up to 30% by volume of the formulation. The colostrum powder can be in freeze-dried or sprayed form.
Più particolarmente, le formulazioni dell'invenzione comprendono collutori liquidi o in bustine da diluire al momento dell'uso, per l'applicazione al cavo orale mediante gargarismi e sciacqui con soluzione non diluita, spray per nebulizzazioni, gel gengivali per massaggi delle gengive, dentifrici o compresse da sciogliere lentamente in bocca. More particularly, the formulations of the invention comprise liquid mouthwashes or in sachets to be diluted at the time of use, for application to the oral cavity by gargling and rinsing with an undiluted solution, nebulization sprays, gingival gels for massaging the gums, toothpastes or tablets to dissolve slowly in the mouth.
Le composizioni dell’invenzione vengono preparate secondo le tecniche farmaceutiche convenzionali per la preparazione di formulazioni topiche per il trattamento del cavo orale. The compositions of the invention are prepared according to conventional pharmaceutical techniques for the preparation of topical formulations for the treatment of the oral cavity.
Le formulazioni dell'invenzione saranno utilizzate dal paziente da 1 a 3 volte al giorno, in particolare la mattina e la sera dopo il lavaggio dei denti. The formulations of the invention will be used by the patient from 1 to 3 times a day, in particular in the morning and in the evening after brushing the teeth.
Secondo un ulteriore aspetto dell'invenzione, le formulazioni possono contenere colostro miscelato ad agenti antibatterici, come la clorexidina e benzidamina, ad agenti antiinflaminatori, ad anestetici locali come lidocaina e benzocaina, ad estratti vegetali ad azione astringente o antiinfiammatoria, come oli essenziali di salvia, di finocchio,di menta e di garofano,e così via. According to a further aspect of the invention, the formulations can contain colostrum mixed with antibacterial agents, such as chlorhexidine and benzydamine, with anti-inflammatory agents, with local anesthetics such as lidocaine and benzocaine, with plant extracts with astringent or anti-inflammatory action, such as essential oils of sage. , fennel, mint and carnation, and so on.
Le formiliazioni conterranno inoltre gli eccipienti convenzionali utilizzati nella preparazione di formulazioni topiche orali. The formiliations will also contain conventional excipients used in the preparation of oral topical formulations.
Gli esempi seguenti illustrano formulazioni secondo la presente invenzione. The following examples illustrate formulations according to the present invention.
ESEMPIO 1 EXAMPLE 1
Gel gengivale 20% di colostro 20% colostrum gingival gel
200 mi di gel contengono (in % in volume): 200 ml of gel contain (in% by volume):
colostro 20 colostrum 20
glicol propilenico 1 propylene glycol 1
clorexidina digluconato 0,5 chlorhexidine digluconate 0.5
p-idrossibenzoato di metile 0,7 methyl p-hydroxybenzoate 0.7
p-idrossibenzoato di propile 0,7 propyl p-hydroxybenzoate 0.7
oli essenziali e aromi 1,2% essential oils and aromas 1.2%
silice micronizzata 10% 10% micronized silica
acqua q.b.a 200 mi water q.s. to 200 ml
ESEMPIO 2 EXAMPLE 2
Collutorio al 30% di colostro 30% colostrum mouthwash
100 mi di collutorio contengono (in % in volume): colostro 30 100 ml of mouthwash contain (in% by volume): colostrum 30
p-idrossibenzoato etile 0,7 benzidamina 0,5 henzocaina 2,5 p-hydroxybenzoate ethyl 0.7 benzydamine 0.5 henzocaine 2.5
aromi naturali 2 natural flavors 2
acqua distillata q.s.a 100 mi distilled water q.s. to 100 ml
ESEMPIO 3 EXAMPLE 3
Gel gengivale 20% di colostro 20% colostrum gingival gel
200 mi di gel contengono (in % in volume): colostro 20 200 ml of gel contain (in% by volume): colostrum 20
silice micronizzata 10 micronized silica 10
olio essenziale di finocchio 1,5 essential oil of fennel 1,5
olio essenziale di salvia 2,0 sage essential oil 2.0
p-idrossibenzoato di metile 1,5 methyl p-hydroxybenzoate 1,5
p-idrossihenzoato di propile 1,5 clorexidina digluconato 0,5 propyl p-hydroxyhenzoate 1,5 chlorhexidine digluconate 0,5
aromi naturali 1,5 natural flavors 1,5
acqua distillata q.s.a 200 mL distilled water q.s. to 200 mL
Claims (6)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001091A IT1291340B1 (en) | 1997-05-09 | 1997-05-09 | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES |
| PCT/EP1998/002613 WO1998051316A1 (en) | 1997-05-09 | 1998-05-04 | Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity |
| AU80153/98A AU8015398A (en) | 1997-05-09 | 1998-05-04 | Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001091A IT1291340B1 (en) | 1997-05-09 | 1997-05-09 | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITMI971091A0 ITMI971091A0 (en) | 1997-05-09 |
| ITMI971091A1 true ITMI971091A1 (en) | 1998-11-09 |
| IT1291340B1 IT1291340B1 (en) | 1999-01-07 |
Family
ID=11377104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT97MI001091A IT1291340B1 (en) | 1997-05-09 | 1997-05-09 | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU8015398A (en) |
| IT (1) | IT1291340B1 (en) |
| WO (1) | WO1998051316A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP327198A0 (en) * | 1998-04-30 | 1998-05-21 | Northfield Laboratories Pty Ltd | A food composition and method of using same |
| FR2783172B1 (en) * | 1998-09-15 | 2001-09-07 | Petit Leon Antoine Georges Le | EQUIDE CONTAINING MILK |
| WO2000059519A2 (en) * | 1999-03-31 | 2000-10-12 | Kapitz Carl Heinz | Active agent and combination of active agents for human beings and animals |
| US20030003059A1 (en) * | 2001-04-03 | 2003-01-02 | Frederic Dana | Dentifrice compositions |
| US6645472B1 (en) * | 2002-09-13 | 2003-11-11 | Michael R. Anderson | Oral hygiene powder composition and method |
| ITMI20051231A1 (en) * | 2005-06-29 | 2006-12-30 | Pharmaproducts Uk Ltd | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND FOLINATED CALCIUM FOR THE TREATMENT OF ORAL CABLE AFFECTIONS |
| ITMI20080174A1 (en) * | 2008-02-05 | 2009-08-06 | You Biomedical Research Srl | TOPIC COMPOSITIONS BASED ON COLOSTRUM, FOLATE AND ROSE HONEY FOR THE TREATMENT OF ORAL CAVITY AFFECTIONS |
| US9492512B2 (en) | 2011-12-30 | 2016-11-15 | Innomed S.A. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3A/C4A, and chemotactic factors |
| ITMI20112446A1 (en) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | COMPOSITION FOR THE THERAPY OF INJURIES OF ORAL MUCOSA |
| RU2642650C2 (en) | 2011-12-30 | 2018-01-25 | Инномед С.А. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cells factors, c3a/s4a complement proteins, immunoglobulins and chemotactic factors |
| IT202000020971A1 (en) * | 2020-09-03 | 2022-03-03 | Solime S R L | PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5833994A (en) * | 1993-01-26 | 1994-08-15 | Horse Vitality Ltd. | Pharmaceutical and dermocosmetic compositions containing equine colostrum |
| EP0743060B1 (en) * | 1995-04-28 | 2002-11-13 | Sara Lee/DE N.V. | Use of dental-care products comprising bovine colostrum |
-
1997
- 1997-05-09 IT IT97MI001091A patent/IT1291340B1/en active IP Right Grant
-
1998
- 1998-05-04 WO PCT/EP1998/002613 patent/WO1998051316A1/en active Application Filing
- 1998-05-04 AU AU80153/98A patent/AU8015398A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IT1291340B1 (en) | 1999-01-07 |
| AU8015398A (en) | 1998-12-08 |
| WO1998051316A1 (en) | 1998-11-19 |
| ITMI971091A0 (en) | 1997-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5648399A (en) | Liquid polymer composition and method of use | |
| US5160737A (en) | Liquid polymer composition, and method of use | |
| Balagopal et al. | Chlorhexidine: the gold standard antiplaque agent | |
| JPH032126A (en) | Oral antifungal preventive and use thereof | |
| ITFI20080035A1 (en) | DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA | |
| US9597276B2 (en) | Composition for the prophylaxis of candidiasis | |
| EP2099416B1 (en) | Anti-calculus dental composition and methods for using same | |
| ES2314304T3 (en) | TOPIC PHARMACEUTICAL COMPOSITIONS CONTAINING PROPER NATURAL ACTIVE PRINCIPLES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY PROCESSES OF MUCOSES. | |
| ITMI971091A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES | |
| Steinberg et al. | Dental drug-delivery devices: local and sustained-release applications | |
| US7087219B2 (en) | Toothpaste containing anticancer agents | |
| WO2007000648A1 (en) | Pharmaceutical formulations containing colostrum and calcium folinate for te treatment of disorders of the oral cavity | |
| JP2000256155A (en) | Oral composition | |
| JPH1112142A (en) | Oral composition | |
| JP2012144480A (en) | Oral cavity composition | |
| EP2630944A1 (en) | Silicon-based particle composition | |
| US20060246016A1 (en) | Toothpaste containing anticancer agents | |
| JP2012111732A (en) | Composition for oral cavity | |
| US20190321308A1 (en) | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene | |
| Swarnalatha et al. | International Journal of Dental Science and Innovative Research (IJDSIR) | |
| Schmidt | Mouthwashes and gargles: oral health | |
| RU2205625C1 (en) | Curative-prophylactic composition for treating teeth | |
| JP2001294536A (en) | Prophylactic/therapeutic preparation for periodontal disease | |
| JPH10152424A (en) | Composition for oral cavity | |
| JPH10167945A (en) | Orally applicable composition containing extract of achyranthes japonica or bark of ulmus macrocapra |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |